Zoryve® (roflumilast) – New indication
May 22, 2025 - Arcutis Biotherapeutics announced the FDA approval of Zoryve (roflumilast) topical foam, for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.
Download PDF
